Browsing by Author "Sevinc, Alper"
Now showing items 1-7 of 7
-
Abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer (MCRPC) after docetaxel chemotherapy: Multicentric experience of Anatolian Society of Medical Oncology
Demirci, Umut; Oflazoglu, Utku; Kodaz, Hilmi; Ciltas, Aydin; Kefeli, Umut; Akyol, Murat; Ozturk, Banu; Geredell, Caglayan; Seker, Mehmet Metin; Clhan, Saner; Tastekin, Dldem; Sevinc, Alper; Akinci, Muhammad Bulent; Uysal, Mukremin; Taskoylu, Burcu Yapar; Duran, Ayse Ocak; Yazici, Omer Komi; Karaoglu, Aziz; Benekli, Mustafa; Buyukberber, Suleyman (AMER SOC CLINICAL ONCOLOGY, 2014)… -
Comparison of survival with somatostatin analog and chemotherapy and prognostic factors for treatment in 165 advanced neuroendocrine tumor patients with Ki-67 20% or less
Ozaslan, Ersin; Karaca, Halit; Koca, Sinan; Sevinc, Alper; Hacioglu, Bekir; Ozkan, Metin; Ozcelik, Melike; Duran, Ayse O.; Hacibekiroglu, Ilhan; Yildiz, Yasar; Tanriverdi, Ozgur; Menekse, Serkan; Aksoy, Asude; Bozkurt, Oktay; Urvay, Semiha; Uysal, Mukremin; Demir, Hacer; Ciltas, Aydin; Dane, Faysal (LIPPINCOTT WILLIAMS & WILKINS, 2017)The objectives of this study were to compare progression-free survival (PFS) with somatostatin analog (SSA) versus chemotherapy (CTx) in first-line therapy and to determine the patient group in which these treatments were ... -
Outcomes of surveillance versus adjuvant chemotherapy for patients with stage IA and IB nonseminomatous testicular germ cell tumors
Gumus, Mahmut; Bilici, Ahmet; Odabas, Hatice; Ustaalioglu, Bala Basak Oven; Kandemir, Nurten; Demirci, Umut; Cihan, Sener; Bayoglu, Ibrahim Vedat; Ozturk, Turkan; Turkmen, Esma; Urakci, Zurat; Seker, Mehmet Metin; Gunaydin, Yusuf; Selcukbiricik, Fatih; Turan, Nedim; Sevinc, Alper (SPRINGER, 2017)Background Currently, it is accepted that risk assessment of clinical stage I (CS I) nonseminomatous germ cell tumors (NSGCT) patient is mainly dependent on the presence of lymphovascular invasion (LVI). Initial active ... -
Outcomes of surveillance VS. adjuvant chemotherapy for patients with STAGE IA and IB NON-seminomatous testicular germ-cell tumors.
Bilici, Ahmet; Gumus, Mahmut; Odabas, Hatice; Kandemir, Nurten; Demirci, Umut; Cihan, Sener; Bayoglu, Ibrahim Vedat; Ustaalioglu, Bala Basak Oven; Ozturk, Turkan; Turkmen, Esma; Urakci, Zuhat; Seker, Mehmet Metin; Gunaydin, Yusuf; Selcukbiricik, Fatih; Turan, Nedim; Sevinc, Alper (AMER SOC CLINICAL ONCOLOGY, 2016)… -
Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas
Cicin, Irfan; Ozatli, Tahsin; Turkmen, Esma; Ozturk, Turkan; Ozcelik, Melike; Cabuk, Devrim; Gokdurnali, Ayse; Balvan, Ozlem; Yildiz, Yasar; Seker, Metin; Ozdemir, Nuriye; Yapar, Burcu; Tanriverdi, Ozgur; Gunaydin, Yusuf; Menekse, Serkan; Oksuzoglu, Berna; Aksoy, Asude; Erdogan, Bulent; Hacioglu, M. Bekir; Arpaci, Erkan; Sevinc, Alper (GALENOS YAYINCILIK, 2016)Background: Prognostic factors and the standard treatment approach for gynaecological carcinosarcomas have not yet been clearly defined. Although carcinosarcomas are more aggressive than pure epithelial tumours, they are ... -
What are the differences between young (25 years) and adults (> 25 years) colorectal cancer (CRC)? An Anatolian Society of Medical Oncology Study.
Kaplan, Muhammet Ali; Urakci, Zuhat; Gumus, Mahmut; Arslan, Ulku Yalcintas; Geredeli, Caglayan; Ozdemir, Nuriye; Koca, Dogan; Oruc, Zeynep; Uysal, Mukremin; Dane, Faysal; Sevinc, Alper; Seker, Mehmet Metin; Aksoy, Asude; Kucukoner, Mehmet; Pilanci, Kezban Nur; Topcu, Turkan Ozturk; Karaagac, Mustafa; Yildiz, Ramazan; Isikdogan, Abdurrahman (AMER SOC CLINICAL ONCOLOGY, 2015)… -
XELOX Plus Bevacizumab vs. FOLFIRI Plus Bevacizumab Treatment for First-line Chemotherapy in Metastatic Colon Cancer: a Retrospective Study of the Anatolian Society of Medical Oncology
Duran, Ayse Ocak; Karaca, Halit; Besiroglu, Mehmet; Bayoglu, Ibrahim Vedat; Menekse, Serkan; Yapici, Heves Surmeli; Yazilitas, Dogan; Bahceci, Aykut; Uysal, Mukremin; Sevinc, Alper; Hacibekiroglu, Ilhan; Aksoy, Asude; Tanriverdi, Ozgur; Arpaci, Erkan; Inanc, Mevlude; Dane, Faysal; Ozkan, Metin (ASIAN PACIFIC ORGANIZATION CANCER PREVENTION, 2014)Background: XELOX plus bevacizumab (XELOX-Bev) and FOLFIRI plus Bevacizumab (FOLFIRI - Bev) treatments are an effective strategies patients with metastatic colorectal cancer (mCRC). The aim of this study was to compare ...
